Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year — even assuming clinical trials are successful.

The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and building a supply chain in Africa for products that must be stored at minus 80 degrees Celsius.

Click Here To Read More